Bone Marrow Transplantation 1957-2019

Elizabeth Simpson, Francesco Dazzi, Elizabeth Simpson, Francesco Dazzi

Abstract

Clinical bone marrow transplantation started in 1957 at a time when remarkably little was known about hematopoietic stems cells, immune responses to transplants or the identity of transplant antigens. This review will delineate the substantial increase in knowledge about these three areas gained between then and 1992 when the Ceppellini School course on Bone Marrow Transplantation was held, along with the progress made in clinical application, as well as the stumbling blocks that remained to be overcome by further research to advance knowledge. It will outline the significant progress made between 1992 and the present year, 2019, and the remaining problems.

Keywords: graft-vs.-host; graft-vs.-tumour; histocompatibility; immunosuppression; transplantation.

Figures

Figure 1
Figure 1
Naples, where Professor Serafino Zappacosta founded the Scuola Superiore d'Immunologia Ruggero Ceppellini in 1991. Image: Vera Maone, used with permission.

References

    1. Thomas ED, Lochte HL, Lu WC, Ferrebee JW. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med. (1957) 257:491–6. 10.1056/NEJM195709122571102
    1. Billingham R, Brent L, Medawar PB. Actively acquired tolerance of foreign cells. Nature. (1953) 172:603–6. 10.1038/172603a0
    1. Barnes DWH, Loutit JF. Protective effects of implantation of spleen tissue. Proc Roy Soc Med. (1953) 46:251.
    1. Medawar PB. The behaviour and fate of skin autografts and homografts in rabbits: a report to the War Wounds Committee of the Medical Research Council. J Anat. (1944) 78:176–99.
    1. Mitchison NA. Passive transfer of transplantation immunity. Nature. (1953) 171:267–8. 10.1038/171267b0
    1. Billingham R, Brent L, Medawar PB. Quantitative studies on tissue transplantation immunity. III. Actively acquired tolerance. Phil Trans Roy Soc B. (1956) 239:357–414. 10.1098/rstb.1956.0006
    1. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. (1975) 256:495–7. 10.1038/256495a0
    1. Hardy RR, Roederer M. Leonard Herzenberg (1931–2013): the life of FACS. Immunity. (2013) 39:989–91. 10.1016/j.immuni.2013.11.008
    1. Uchida N, Weissman IL. Searching for haematopoietic stem cells: evidence that Th1/1lo Lin-Sca-1+ cells are the only stem cells in C57BL/Ka-Thy-1.1 bone marrow. J Exp Med. (1992) 175:175–84. 10.1084/jem.175.1.175
    1. Dazzi F, Szydlo RM, Craddock C, Cross NCP, Kaeda J, Chase A, et al. . Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood. (2000) 95:67–71.
    1. Snell GD. Methods for the study of histocompatibility genes. J Genet. (1948) 49:87–108. 10.1007/BF02986826
    1. Bodmer WF. In memoriam Ruggero Ceppellini 1917–1988. Immunogenetics. (1989) 29:145–7. 10.1007/BF00373638
    1. Ceppellini R, Mattiuz PL, Scudeller G, Visetti M. Experimental allotransplantation in man I. The role of the HLA system in different genetic combinations. Transplant Proc. (1969) 1:385–9.
    1. Amos DB, Bach FH Phenotypic expressions of the major histocompatibility in man (HL-A), leucocyte antigens and mixed lymphocyte culture reactivity. J Exp Med. (1968) 128:623–39. 10.1084/jem.128.4.623
    1. Simpson E, O'Hopp S, Wunderlich J. Life span of cytotoxic activity & memory activity following allogeneic skin grafting in the mouse. Transplantation. (1974) 18:374–7. 10.1097/00007890-197410000-00014
    1. Janeway CA, Jr., Sharrow SO, Simpson E. T cell populations with different functions. Nature. (1975) 253:544–6. 10.1038/253544a0
    1. Gordon RD, Simpson E, Samelson LE. In vitro cell-mediated immune responses to the male specific (H-Y) antigen in mice. J Exp Med. (1975) 142:1108–20. 10.1084/jem.142.5.1108
    1. Goulmy E, Termijtelen A, Bradley BA, van Rood JJ. Y-antigen killing by T cells of women restricted by HLA. Nature. (1977) 266:544–5. 10.1038/266544a0
    1. Borkmann PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature. (1987) 329:512–8. 10.1038/329512a0
    1. Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A, et al. . A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med. (1992) 176:1453–7. 10.1084/jem.176.5.1453
    1. Chiusolo P, Bug G, Olivieri A, Mats B, Mordini N, Alessandrino PE, et al. A modified post-transplant cyclophosphamide (PT-CY) regimen, following unmanipulated haploidentical bone marrow transplantation, for acute myeloid leukemia: a multicenter study. Blood. (2016) 128:1234–49. 10.1016/j.bbmt.2018.01.031
    1. McCurdy SR, Fuchs EJ. Selecting the best haploidentical donor. Semin Hematol. (2016) 53:246. 10.1053/j.seminhematol.2016.08.001
    1. McCurdy SR, Zhang M-J, St. Martin A, Al Malki MM, Bashey A, Gaballa S, et al. . Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide. Blood Adv. (2018) 2:299. 10.1182/bloodadvances.2017014829
    1. Wagner JE, Brunstein CG, Boitano AE, DeFor DE, McKenna D, Sumstad D, et al. . Phase I/II trial of stem regenin-1 expanded umbilical cord blood hematopoietic stem cells supports testing as a stand-alone graft. Cell Stem Cell. (2016) 18:144–55. 10.1016/j.stem.2015.10.004
    1. Morgan RA, Gray D, Lomova A, Kohn DB. Haematopoietic stem cell therapy: progress and lessons learned. Cell Stem Cell. (2017) 21:574–90. 10.1016/j.stem.2017.10.010
    1. Fozza C, Szydlo RM, Abdel-Rehim MM, Nadal E, Goldman JM, Apperley JF, et al. . Factors for graft-versus-host disease after donor lymphocyte infusions with an escalating dose regimen: lack of association with cell dose. Br J Haematol. (2007) 136:833–6. 10.1111/j.1365-2141.2007.06501.x
    1. Luznik L, O'Donnell PV, Ephraim JF. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical BMT. Semin Oncol. (2012) 39:683–93. 10.1053/j.seminoncol.2012.09.005
    1. Brunstein CG, Miller JS, McKenna DH, Hippen KL, DeFor TE, Sumstad D, et al. . Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. Blood. (2016) 127:1044–51. 10.1182/blood-2015-06-653667
    1. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, et al. . Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood. (2003) 101:3722–9. 10.1182/blood-2002-07-2104
    1. Galleu A, Riffo-Vasquez Y, Trento C, Lomas C, Dolcetti L, Cheung TS, et al. . Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. Sci Transl Med. (2017) 9:416. 10.1126/scitranslmed.aam7828
    1. Galleu A, Milojkovic D, Deplano S, Szydlo R, Loaiza S, Wynn R, et al. . Mesenchymal stromal cells for acute graft-versus-host disease: response at 1 week predicts probability of survival. Br J Haematol. (2019) 185:89–92. 10.1111/bjh.15749

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir